Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 6/20 | 0.53 |
| ▸ | GSK3B | P49841 | 10/20 | 0.48 |
| ▸ | GNG2 | P59768 | 1/20 | 0.47 |
| ▸ | GNB1 | P62873 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367013 | 0.86 | PTPN1 (0.53) | PTPN1GSK3BGNG2GNB1MAPT | |
| SCHEMBL4342176 | 0.86 | PTPN1 (0.53) | PTPN1GSK3BGNG2GNB1MAPT | |
| SCHEMBL20202559 | 0.85 | MAPT (0.55) | MAPTALDH1A1HPGDTSHRRAB9A | |
| SCHEMBL366866 | 0.81 | PTPN1 (0.61) | PTPN1GSK3BRAB9A | |
| SCHEMBL29628387 | 0.81 | PTPN1 (0.61) | PTPN1GSK3BRAB9A | |
| SCHEMBL4345488 | 0.80 | HDAC1 (0.56) | PTPN1GSK3BGNG2GNB1ALDH1A1 | |
| SCHEMBL11808028 | 0.80 | GSK3B (0.55) | PTPN1GSK3BGNG2GNB1ALDH1A1 | |
| SCHEMBL6180535 | 0.79 | MAOB (0.51) | MAPTALDH1A1 | |
| SCHEMBL4124943 | 0.79 | EPHX2 (0.55) | MAPTALDH1A1HPGDTSHRRAB9A | |
| SCHEMBL1701124 | 0.78 | PTPN1 (0.57) | PTPN1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2023-09-21 | — | — | US | disclosed |
| EP-1507530-B1 | DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2005-11-02 | — | — | EP | disclosed |
| EP-1507530-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-6818663-B2 | AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS | HOFFMANN-LA ROCHES | 2004-11-16 | — | — | US | disclosed |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CHU XIN-JIE (US) | 2004-01-08 | — | — | US | disclosed |
| WO-2003097048-A1 | DIAMINOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295154-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | PTPN1 499/4885GSK3B 1798/4885GNG2 371/4885 |
| US-20040006058-A1 | DIAMINOTHIAZOLES | CDK4, CDK1, CDK2 | PTPN1 2400/4885GSK3B 344/4885GNG2 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.